Quoin Pharmaceuticals Provides Corporate Update and

Quoin announced dosing of first patient in double blinded clinical study to evaluate QRX003 for Netherton SyndromeQuoin announced initiation of a second...

Related Keywords

Australia ,Uquoin ,Queensland ,Michael Myers ,Linkedin ,Queensland University Of Technology ,Quoin Pharmaceuticals Ltd ,Drug Administration ,Nasdaq ,Company Or Quoin ,Company Annual Report On Form ,Exchange Commission ,Netherton Syndrome ,Queensland University ,Early Access Programs ,Investigational New Drug ,Compassionate Use ,Annual Report ,Peeling Skin Syndrome ,Palmoplantar Keratoderma ,Epidermolysis Bullosa ,Private Securities Litigation Reform Act ,Consolidated Statements ,Ended December ,Nasdaq Qnrx ,Quoin Pharmaceuticals ,Nc ,